A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA (vol 36, pg 1190, 2019)

Johansen Pierre; Hunt Barnaby; Iyer Neeraj N.; Tam Dang-Tan; Pollock Richard F.

首页> 外文期刊>Advances in therapy. >A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA (vol 36, pg 1190, 2019)

【24h】

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA (vol 36, pg 1190, 2019)

机译：对次每周半蛋白质的对照分析的相对成本与烯肽延长释放和杜拉格拉蛋白剂，用于将患者带到美国的HBA1C和体重减轻治疗目标（Vol 36，PG 1190,2019）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Advances in therapy. 》 |2019年第5期| 共1页
作者
Johansen Pierre; Hunt Barnaby; Iyer Neeraj N.; Tam Dang-Tan; Pollock Richard F.;
展开▼
作者单位

Novo Nordisk AS Soborg Denmark;

Ossian Hlth Econ &

Commun GmbH Basel Switzerland;

Novo Nordisk Inc Plainsboro NJ USA;

Novo Nordisk Inc Plainsboro NJ USA;

Ossian Hlth Econ &

Commun GmbH Basel Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学 ;
关键词

相似文献

外文文献

1. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA (vol 36, pg 1190, 2019) [J] . Johansen Pierre, Hunt Barnaby, Iyer Neeraj N., Advances in therapy. . 2019 ,第5期

机译：对次每周半蛋白质的对照分析的相对成本与烯肽延长释放和杜拉格拉蛋白剂，用于将患者带到美国的HBA1C和体重减轻治疗目标（Vol 36，PG 1190,2019）
2. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States [J] . Lars Wilkinson, Barnaby Hunt, Pierre Johansen, Diabetes therapy . 2018 ,第3期

机译：在美国，每周一次Semaglutide与Dulaglutide达成HbA1c治疗目标的成本和体重减轻反应
3. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type?2 Diabetes: A Cost of Control Analysis in Spain [J] . Josep Vidal, Samuel J. P. Malkin, Barnaby Hunt, Diabetes therapy . 2020 ,第2期

机译：每周半蛋白质的短期成本效果与一次每日SitaGliptin和一次每周达拉蛋白质进行一次治疗2型糖尿病患者：西班牙的控制分析成本
4. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States [O] . Lars Wilkinson, Barnaby Hunt, Pierre Johansen, 2018

机译：在美国每周一次Semaglutide与Dulaglutide达成HbA1c治疗目标的成本和体重减轻反应
5. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK [O] . Pierre Johansen, Anna Sandberg, Matthew Capehorn 2020

机译：一次每周半蛋白质与exenatide延长释放，杜拉格拉蛋白质和Liraglutide在英国的相对对照分析的相对成本

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA (vol 36, pg 1190, 2019)

著录项

相似文献

相关主题

期刊订阅